U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20F3N3O3
Molecular Weight 395.3756
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORBIFLOXACIN

SMILES

C[C@H]1CN(C[C@@H](C)N1)C2=C(F)C3=C(C(=O)C(=CN3C4CC4)C(O)=O)C(F)=C2F

InChI

InChIKey=QIPQASLPWJVQMH-DTORHVGOSA-N
InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+

HIDE SMILES / InChI

Molecular Formula C19H20F3N3O3
Molecular Weight 395.3756
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Orbifloxacin (brand name Orbax) is a fluoroquinolone antibiotic which is approved for use in dogs and cats, abd marketed by Schering-Plough Animal Health. Orbifloxacin is a synthetic broad-spectrum antibacterial agent from the class of fluoroquinolone carboxylic acid derivatives. Orbifloxacin is the international nonproprietary name for 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid. ORBAX® Oral Suspension is a malt flavored antibiotic suspension containing 30 mg/mL of orbifloxacin and sorbic acid as a preservative. ORBAX® Oral Suspension is indicated for the treatment of urinary tract infections (cystitis) and also for skin and soft tissue infections (wounds and abscesses). Orbifloxacin is bactericidal against a wide range of gram-negative and gram-positive organisms and exerts its antibacterial effect through interference with the bacterial enzyme DNA gyrase which is needed for the maintenance and synthesis of bacterial DNA.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ORBAX
Primary
ORBAX
PubMed

PubMed

TitleDatePubMed
Single-step extraction followed by LC for determination of (fluoro)quinolone drug residues in muscle, eggs, and milk.
2010 Apr
Patents

Patents

Sample Use Guides

In Vivo Use Guide
for dogs: oral Suspension is 1.1 to 3.4 mg/lb (2.5 to 7.5 mg/kg) of body weight administered once daily
Route of Administration: Oral
In Vitro Use Guide
The minimum inhibitory concentrations (MICs) of orbifloxacin against 240 field S. intermedius isolates (69 skin and 171 ear isolates) ranged from 0.016 to 8 mg l(-1), with MIC50 and MIC90 equal to 0.5 and 1 mg l(-1), respectively.
Substance Class Chemical
Created
by admin
on Tue Mar 06 11:25:18 UTC 2018
Edited
by admin
on Tue Mar 06 11:25:18 UTC 2018
Record UNII
660932TPY6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ORBIFLOXACIN
GREEN BOOK   INN   MART.   MI   USP   USP-RS  
INN  
Official Name English
ORBIFLOXACIN [USP-RS]
Common Name English
ORBIFLOXACIN [MI]
Common Name English
ORBIFLOXACIN [GREEN BOOK]
Common Name English
ORBIFLOXACIN [MART.]
Common Name English
ORBIFLOXACIN [INN]
Common Name English
1-CYCLOPROPYL-7-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)-5,6,8-TRIFLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID
Systematic Name English
ORBIFLOXACIN [USP]
Common Name English
ORBAX
Brand Name English
ORBIFLOXACIN [JAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01MA95
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
CFR 21 CFR 520.1616
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
CFR 21 CFR 524.1610
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
CFR 21 CFR 520.1618
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
Code System Code Type Description
EVMPD
SUB09454MIG
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
INN
7025
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
CAS
113617-63-3
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
WIKIPEDIA
ORBIFLOXACIN
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
EPA CompTox
113617-63-3
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
NCI_THESAURUS
C72635
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
RXCUI
995897
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY RxNorm
MERCK INDEX
M8227
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY Merck Index
ChEMBL
CHEMBL295433
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
PUBCHEM
60605
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY SWITZERF
MESH
C095163
Created by admin on Tue Mar 06 11:25:18 UTC 2018 , Edited by admin on Tue Mar 06 11:25:18 UTC 2018
PRIMARY
Related Record Type Details
ACTIVE MOIETY